We are live on ! Find out more
GNRX

VanEck Vectors Generic Drugs ETF
GNRX

Delisted

GNRX was delisted on the 4th of April, 2019.

Back to rankings

2 hedge funds and large institutions have $1.33M invested in VanEck Vectors Generic Drugs ETF in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.32M
2
TRCT
Tower Research Capital (TRC)
New York
+$6.98K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$1.32M +$1.32M +55,000 New
TRCT
2
Tower Research Capital (TRC)
New York
$7K +$6.98K +291 New

GNRX Hedge Fund Activity: Q1 2016 in Review

2 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q1 2016, worth a combined $1.33M.

Buyers outnumbered sellers: 2 funds opened new GNRX positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $1.32M.

  • 2 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q1 2016, up from 0 in Q4 2015.
  • Funds reported $1.33M of VanEck Vectors Generic Drugs ETF stock for Q1 2016.
  • 2 funds opened new VanEck Vectors Generic Drugs ETF positions in Q1 2016 and 0 closed out, a net change of +2 holders.
  • The largest VanEck Vectors Generic Drugs ETF buyer in Q1 2016 was UBS Group, an estimated $1.32M added.

Based on aggregated 13F filings for Q1 2016.